The Food and Drug Administration on Tuesday approved Genentech's drug Ocrevus for adults with severe forms of multiple sclerosis.
The intravenous drug represents a new treatment for relapsing forms of MS and the first treatment for primary progressive MS — the most disabling form of the disease.
About 15 percent of MS patients are diagnosed with PPMS, which occurs when a patient's symptoms steadily worsen with any relapses or remissions, according to the CDC.
Genentech expects Ocrevus to be available in the U.S. by mid-April, according to a company news release.
More articles on supply chain:
7 must-reads for supply chain leaders this week
America's focus on technology — rather than medicine — is 'eroding our national intellect,' says pharma exec
Bill Ackman calls $4B Valeant investment 'huge mistake'